Target intelligence / Profile preview

Pancreas-associated transcription factor 1a (PTF1A)

Target
PTF1A
Molecular classification
Transcription factor, Class A basic helix-loop-helix (bHLH) protein
01

Overview

Pancreas-associated transcription factor 1a (PTF1A) is a pancreas-restricted transcription factor of the basic helix-loop-helix (bHLH) family, serving as a key component of the multiprotein PTF1 complex. It is indispensable for pancreas development, guiding progenitor cells toward pancreatic organogenesis, acinar cell differentiation, and maintaining transcriptional programs for exocrine function. In addition to pancreatic roles, PTF1A is crucial for the proper specification of certain neural cell lineages, notably in the cerebellum. Loss-of-function mutations or regulatory disruption result in severe developmental defects such as pancreatic and cerebellar agenesis, neonatal diabetes, and exocrine insufficiency. Dysregulation can also contribute to pancreatic cancer, highlighting its importance as a tumor suppressor[1][2][3].

Other names
Pancreas transcription factor 1 subunit alphaBHLHA29bHLHa29PTF1-p48p48Pancreas-specific transcription factor 1aClass A basic helix-loop-helix protein 29Exocrine pancreas-specific transcription factor p48PTF1PTF1APACAPAGEN2
02

Mechanism of action

PTF1A is not a direct drug target; therapeutic modulation would likely be via gene/protein expression or activity, but this is experimental, not clinical practice.

03

Biological functions

Pancreas organogenesisSpecification/maintenance of pancreatic progenitor and acinar cell identityRegulation of exocrine pancreas-specific gene expression (digestive enzymes: amylase, elastase)Cell fate determination (pancreatic vs. duodenal)Development of cerebellar and neural cell typesMaintenance of acinar cell identity and secretory function
04

Disease associations

Pancreatic agenesis (including permanent neonatal diabetes mellitus)Exocrine pancreatic insufficiencyCerebellar agenesisPancreatic ductal adenocarcinoma (tumor suppressor role)Other developmental defects
05

Safety considerations

As a developmental transcription factor, therapeutic targeting would pose risks for off-target effects in organogenesis, cell differentiation, and potentially neurodevelopment.Disruption or mis-expression can cause profound developmental disorders
06

Biomarkers

Loss-of-function or regulatory mutations can serve as biomarkers for pancreatic agenesis, neonatal diabetes, and cerebellar defectsReduced expression in ductal type pancreatic cancers and some neural tissue pathologies

Beyond the preview

Go deeper on Pancreas-associated transcription factor 1a (PTF1A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pancreas-associated transcription factor 1a (PTF1A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call